Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biogen and Denali’s pivotal trial of a first-in-class LRRK2 kinase inhibitor is a long-awaited test of a target that could provide a path to disease-modifying therapies for Parkinson disease.
Our Future Health CEO Andrew Roddam discusses the UK’s largest-ever health research programme, an ambitious attempt to tackle prevention, detection and treatment of common diseases.
Artificial intelligence tools are increasingly being applied in the development and use of medicines. Here, we provide a regulatory perspective on such applications.
Recently retired head of vaccine R&D at Pfizer, Kathrin Jansen, discusses the lightning speed development of SARS-CoV-2 vaccines — and the implications for vaccine platforms.
MYC, one of the most commonly dysregulated proteins in cancer, has long seemed ‘undruggable’. Can a clinical-stage cell-penetrating peptide — or preclinical small-molecule inhibitors and degraders — prove otherwise?